Objective Glutamate is the most abundant excitatory transmitter in the brain. However, very few models exist to explore the potential of drugs that modulate glutamate transmission. Because altered glutamate transmission is involved in numerous psychiatric diseases, there is a strong need for such models, to characterise the effects of hypo- and hyper-glutamatergic states on the onset and development of such diseases. AGLAEA will develop and characterise models of selective, partial knockdown of specific components of the brain glutamatergic system in mice. This will provide better comprehension of the implication of glutamate signalling in diseases such as schizophrenia, anxiety and cognitive disorders. AGLAEA will lead to breakthrough research on the neurobiological and neurochemical bases of psychiatric disorders and will enable the further testing of new drugs for treatment. In order to selectively turn off specific components of the glutamatergic pathways, an siRNA approach will be used. The effect of modulation of glutamate signalling will be characterised using functional MRI (fMRI) and microdialysis/microsensor analysis. Specific behavioural tests will be carried out on live animals for the assessment of glutamate-related psychiatric disorders. Furthermore, the data collected from siRNA experiments will be applied to the generation of transgenic mice, in which modulation of glutamate signaling will be induced at different stages of development. Therefore, AGLAEA will provide both the pharmaceutical and the academic world with potent models. These models will be used to test novel compounds and assess their therapeutic value and will benefit researchers investigating the neurobiological and neurochemical bases of those diseases.The consortium set up to reach the objectives of AGLAEA gathers 3 high tech SMEs, 2 academic groups and one large group for the management of the project (ALMA), representing all together 4 European countries (FR, HU, UK, NL). Fields of science natural sciencesbiological sciencesneurobiologysocial sciencespsychologybehavioural psychologynatural sciencesbiological sciencesbiochemistrybiomoleculesproteinsmedical and health sciencesclinical medicinepsychiatryschizophrenia Programme(s) FP6-LIFESCIHEALTH - Life sciences, genomics and biotechnology for health: Thematic Priority 1 under the Focusing and Integrating Community Research programme 2002-2006. Topic(s) LSH-2005-2.1.3-7 - Characterisation and use of animal models for neurological and psychiatric diseases IST - Information society technologies Call for proposal FP6-2005-LIFESCIHEALTH-7 See other projects for this call Funding Scheme STREP - Specific Targeted Research Project Coordinator ADDEX PHARMACEUTICALS FRANCE SAS EU contribution No data Address Immeuble Alliance, Bâtiment A & C ARCHAMPS France See on map Links Website Opens in new window Total cost No data Participants (5) Sort alphabetically Sort by EU Contribution Expand all Collapse all BIOTALENTUM LTD. Hungary EU contribution No data Address Aulich Lajos u. 26. GODOLLO See on map Links Website Opens in new window Total cost No data UNIVERSITY OF NOTTINGHAM United Kingdom EU contribution No data Address University Park NOTTINGHAM See on map Links Website Opens in new window Total cost No data UNIVERSITY OF GRONINGEN Netherlands EU contribution No data Address Broerstraat 5 GRONINGEN, POSTCAL CODE: 9712 GL See on map Links Website Opens in new window Total cost No data BRAINS-ON-LINE Netherlands EU contribution No data Address 770 GRONINGEN See on map Links Website Opens in new window Total cost No data ALMA CONSULTING GROUP SAS France EU contribution No data Address Domaine des Bois d'Houlbec 27120 HOULBEC-COCHEREL See on map Links Website Opens in new window Total cost No data
